Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine DevelopmentThe companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine developmentIntravac.
First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at the World Vaccine Conference on April 3rd 2024 in Washington, DC BILTHOVEN, The Netherlands, March 26, 2024 (GLOBE NEWSWIRE) Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive clinical data of a first in human (FIH)
Intravacc B.V.: Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Intravacc B.V.: Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.